Mapi Pharma Sets For $50M Nasdaq IPO

January 28, 2016 | Israeli biomedical company Mapi Pharma has set terms for a $50 million Nasdaq IPO at a company valuation of $194 million, offering 3.1 million shares at a price range of $15 to $17 under ticker symbol MAPI. The Ness Ziona based company is developing extended-release formulations of existing drugs including Teva’s multiple sclerosis treatment Copaxone. Founded in 2008, Mapi previously filed in 2014 and 2015 for an IPO but postponed its offering but is now going ahead despite the difficult market conditions.